NPS-2143 HCL 是一种口服具有活性的溶钙剂，是钙敏感受体(CaSR)的选择性拮抗剂。它能够激活表达人 Ca2+受体的 HEK 293 细胞中的 Ca2+受体，从而增加胞浆 Ca2+浓度(IC50=43 nM)。

NPS-2143 is a selective potent calcium ion-sensing receptor antagonist.

NPS 2143, even when tested at much higher concentrations (3 microM), did not affect the activity of a number of other G protein-coupled receptors, including those most structurally homologous to the Ca2+ receptor. NPS 2143 stimulated parathyroid hormone (PTH) secretion from bovine parathyroid cells (EC50 of 41 nM) over a range of extracellular Ca2+ concentrations and reversed the effects of the calcimimetic compound NPS R-467 on [Ca2+]i and on secretion of PTH . The first reported calcilytic compound was NPS 2143, an orally active molecule which elicits rapid, 3- to 4-fold increases in circulating levels of PTH.

When infused intravenously in normal rats, NPS 2143 caused a rapid and large increase in plasma levels of PTH. Ca2+ receptor antagonists are termed calcilytics and NPS 2143 is the first substance (either atomic or molecular) shown to possess such activity [1]. When administered together with an antiresorptive agent (estradiol), NPS 2143 causes an increase in trabecular bone volume and bone mineral density in osteopenic rats.

324523-20-8

C24H26Cl2N2O2

445.38

NPS-2143 HCL;2-氯-6-[(2R)-3-[[1,1-二甲基-2-(2-萘基)乙基]氨基]-2-羟基丙氧基]苯腈盐酸盐

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years